Bottom line
“Peptide” is the name for a broad group of chemicals. Some peptide medicines have strong evidence from studies in people. They also have uses approved by the FDA (the U.S. Food and Drug Administration). Other peptides that are promoted have little or no useful evidence from studies in people. What can be said about any of them depends on the exact molecule, product, use, and evidence.10134
- Evidence in people
- Depends on the product and the use
- Approval status
- This guide covers a group with mixed approval status and mixed evidence. It includes FDA-approved peptide medicines and compounded drugs (custom versions of a drug mixed by pharmacies). It also includes peptides that are still being studied and not approved. These differ in both approval and evidence, and none can stand in for another.13111
Where research exists
Filled markers show which stages of research this guide covers. They don't rate how well something works, how safe it is, or how good the studies are.
- Health results in peopleCovered in this guide
- Blood tests and body measurements in peopleCovered in this guide
- Animal studiesCovered in this guide
- Lab studies in cellsCovered in this guide
- Untested idea or marketing claimCovered in this guide
What a peptide is
A peptide is a chain of amino acids (the building blocks of proteins). How it behaves depends partly on its sequence (the order of its amino acids) and its length. It also depends on how it folds and moves in three dimensions. Chemical changes to the molecule matter too, and so does its formulation (the mix of ingredients and the form of the final product). Two molecules can both be peptides and still be unrelated as medicines.109
Some peptides are made inside the body. These are called endogenous peptides. They may act as signals between cells or organs. Learning what one does in the body's normal workings can suggest an idea for a treatment. Showing that a lab-made version improves health when given as a treatment takes separate evidence from people.205
The FDA reviews each approved peptide medicine as a specific product. The review covers specific uses and specific groups of people. That approval and the product's label don't automatically extend to a different peptide or a different formulation. They don't automatically cover a use that isn't on the label either. The same goes for an unapproved version sold under a familiar ingredient name.131411
Compounded drugs are made for particular situations under sections of federal law. But they are not FDA-approved. The FDA does not review each compounded drug for safety, effectiveness, or quality before it is sold.1112
Investigational or “research” peptides have not been approved. They range from molecules in formal drug-development programs to substances backed only by lab work or marketing claims. A “research use” label does not mean regulators have endorsed the peptide. It does not grade the evidence either. It says nothing about whether the peptide is suitable for people.17
So “peptide” is the name of a chemical group. Benefit and safety have to be shown for each molecule and each product, for each proposed use.109
Why people are interested in peptides
Peptides can take part in the body's signaling pathways (chains of chemical messages between cells). These pathways relate to appetite, metabolism (how the body turns food into energy), inflammation, how tissues respond, and other functions. That wide reach is one reason peptide science produces both important medicines and many early ideas.131920 A believable pathway is a reason to study an idea. How patients actually do still has to be measured.
The success of one approved peptide medicine can make the whole group sound proven. Take a semaglutide or tirzepatide product that has been studied, such as Wegovy or Zepbound. Its results can't be used as proof for BPC-157, KPV, TB-500, MOTS-c, or a compounded version that hasn't been reviewed.13143465
Words such as “repair,” “recovery,” “anti-aging,” and “optimization” often pack several different questions into one promise. To check one, ask what was measured, in which species, and in which group of people. Ask what it was compared with, for how long, and which material was used.1810
Reading studies in people
Studies of how people actually fare (human outcomes) are the most direct evidence. A randomized trial assigns people to groups by chance. It can compare a defined product with a placebo (a dummy treatment) or with another treatment. It can also measure results that matter to patients. Even then, several things shape what the result means. They include who was studied and for how long. They also include how much data went missing, what health problems came up, and how many people stopped treatment.151617
Some studies in people measure biomarkers (signs that can be measured, such as levels in the blood). Others look at what a substance does in the body (pharmacology). These studies can show how much of a substance is in the body, a change in a lab test, or a link between two things. That does not prove that people feel better, function better, avoid disease, or live longer. For example, one study measured the body's own MOTS-c after exercise. It gave no one MOTS-c.215
Small reports with no comparison group can raise questions about whether a treatment is practical to test. They can also point to a possible effect. But they are easily thrown off. The placebo effect, who was picked to take part, bias in how results were measured, and chance can all skew them. Another trap is regression to the mean (unusually high or low readings tend to drift back toward average on their own). Reporting these small studies as proof that a treatment works overstates them.318
Sometimes no useful study has been found in which people were given a peptide. Then its benefit and safety in people are unknown.465
What animal and cell research can show
Animal research can test how a substance works and where it goes in the body. It can look for early signs of harm, and it can show whether an idea is worth taking further. It cannot show that a human patient will get the same benefit or face the same risk.1820
Experiments in cells and test tubes can show that a molecule acts on a pathway under controlled conditions. In people, things can be very different. That includes how much of the molecule is present, how much the body takes in, and how the body breaks it down. It also includes how the immune system responds and the effects on the whole body.1910
Animal and lab studies are what scientists call preclinical research. Saying evidence comes from them describes its stage. This kind of work is useful for forming and testing ideas. On its own, it is not enough to support a claim that something treats patients.3465
Safety and product quality
Evidence applies to the material that was studied. Many details can change how much reaches the body, how stable the product is, and how risky it is. One is what the substance really is. Others are its salt form (the molecule paired with another chemical, such as acetate) and any chemical changes. If only part of a larger molecule is used, the length of that fragment matters. The route matters too (such as swallowing or injecting), and so do the formulation, purity, and sterility (freedom from germs). So do storage and quality controls during manufacturing.936
Impurities related to the peptide, and clumps of peptide molecules stuck together, may change whether the body's immune system reacts against the product. That risk depends on the molecule and the product. Calling a peptide “natural” does nothing to settle it.97
Sometimes no harm has been reported. That is weak comfort when no one knows how many people have used the product. The same is true when studies are small, people were followed for a short time, or reporting is incomplete. “No warning sign found” means much less than “shown to be safe.”4511
Some facts are specific to both the product and the patient. These include reasons a person should not use it, interactions with other drugs, and concerns in pregnancy. They also include problems with organs such as the liver or kidneys, the checkups needed, and side effects. A label for the whole group, or a good result in an animal study, cannot replace that information.101314
What FDA terms mean
FDA approval applies to one defined drug product, the use on its label, and the evidence behind it. Other uses of the same ingredient may never have been reviewed. The same goes for other products advertised under the ingredient's name.1311
Compounding can meet an important need in certain situations. But a compounded drug is not a generic drug, and it is not FDA-approved. Before it goes on sale, the FDA does not give it the same review for safety, effectiveness, and quality that approved drugs get.1112
Some discussions ask whether a bulk ingredient (a raw drug ingredient) belongs on a section 503A or 503B list. The 503A bulks list is the FDA's list of ingredients that pharmacies may use to make custom medicines. The 503B bulks list does the same for outsourcing facilities, which compound drugs on a larger scale. Such a discussion is about a compounding route. Putting an ingredient on a list, leaving it off, or a committee's recommendation does not approve any drug. None of these shows that a drug works in patients.212
FDA advisory committees are groups of outside experts who give the agency independent advice. Their discussions and votes can inform the FDA. But the FDA does not have to follow their recommendations, and the final decision rests with the FDA.8
Questions to ask about a peptide claim
1. What exact molecule, and which form of it, was studied? 2. Is the product being promoted the same material, made up the same way and taken the same way? Or is evidence being borrowed from a salt form, a fragment, the body's own version of the molecule, or a different product?3611
3. Did the evidence come from how people actually fared, from biomarkers measured in people, from animals, or from cells? 4. If people were studied, how many took part? What were they compared with, and for how long? How many stopped treatment, and how much data went missing?153
5. Was the result something patients feel or experience, or only a lab measurement? 6. Are absolute results and harms shown next to claims about relative change (such as “cuts the risk in half”) or how the peptide works? Absolute results count how many people in a group were helped or harmed.1621
7. Is the statement about FDA approval, whether a peptide may be compounded, an advisory committee vote, or a stage of research? Are those being mixed up? 8. What is still unknown about quality, sterility, impurities, immune reactions, drug interactions, and longer-term safety?8911
Four kinds of peptide
Before weighing a health claim, work out which kind of peptide it concerns.
Peptides the body makes (endogenous peptides)
Signals made inside the body. Finding out what one normally does can suggest an idea for a treatment. The benefit and safety of a lab-made version given as a treatment still have to be shown.
FDA-approved peptide medicines
Specific products the FDA has reviewed for set uses and groups of people. Their evidence and labels do not automatically carry over to another molecule, formulation, or use.
Compounded drugs
Custom preparations for a specific patient, made under the laws that cover compounding. They are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they are sold.
Peptides still being studied (investigational or research peptides)
Substances at many stages of research, sometimes with no useful data on their use in people. A research label says nothing about benefit or safety.
The kind of peptide is a starting point. What can be said depends on the exact molecule, product, use, and evidence.
Expert conversation
Peptides 101: The Science of Cellular Signaling, Repair, and Longevity
Chris Renna, DO · 54:47 · Published 2026-02-24
A conversation with an outside expert, for more background. Chris Renna, DO, did not review or endorse this guide.
References
- 1July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration · 2026-07-23 · FDA document
The meeting record lists the substances proposed for the list and the uses discussed. The committee's votes are advice only. They are not an FDA approval or a final FDA decision.
- 22026 PCAC Voting QuestionsU.S. Food and Drug Administration · 2026-07-23 · FDA document
The questions ask whether the free-base and acetate forms should be placed on the 503A bulks list. Drug approval was outside their scope.
- 3BPC-157 Free Base and Acetate Salt: Pharmacy Compounding Advisory Committee Briefing DocumentU.S. Food and Drug Administration · 2026-07-23 · FDA document
The FDA staff's review of the proposed use for ulcerative colitis, written for the compounding review. The studies in people it found were small, short and too weak to show that it works or is safe.
- 4KPV Free Base and Acetate Salt: Pharmacy Compounding Advisory Committee Briefing DocumentU.S. Food and Drug Administration · 2026-07-23 · FDA document
The FDA found no studies of KPV in people and no data from people given it in any way. The memo is the FDA staff's review, written for the compounding review.
- 5MOTS-c Free Base and Acetate Salt: Pharmacy Compounding Advisory Committee Briefing DocumentU.S. Food and Drug Administration · 2026-07-23 · FDA document
FDA identified no studies that gave MOTS-c to humans. Measuring the body's own MOTS-c in people is a different thing from testing it as a treatment.
- 6TB-500: Pharmacy Compounding Advisory Committee Briefing DocumentU.S. Food and Drug Administration · 2026-07-23 · FDA document
The FDA reviewed TB-500 as a short lab-made fragment (acetylated LKKTETQ) and found no studies or data from people given it. Evidence for the full natural protein, thymosin beta-4, applies only to that protein.
- 7Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration · 2026-07-23 · FDA document
FDA's current compounding-risk summary includes BPC-157, KPV, MOTS-c, and the thymosin beta-4 fragment known as TB-500. The listing flags risks and stops well short of a complete safety profile.
- 8Advisory Committees: Critical to the FDA's Product Review ProcessU.S. Food and Drug Administration · 2018-01-04 · FDA document
The FDA explains that the committee only gives advice, which the FDA does not have to follow, and that the FDA makes the final decision.
- 9Immunogenicity Risk of Peptide Drug Products: Scientific and Regulatory ConsiderationsU.S. Food and Drug Administration · 2024-09-11 · FDA document
How a peptide is made up and given, clumping, and impurities can all change the risk of immune reactions. This is a general rule. Each product still has to be tested on its own.
- 10Clinical Pharmacology Considerations for Peptide Drug ProductsU.S. Food and Drug Administration · 2023-12-01 · FDA document
This is draft advice from the FDA, which drug makers do not have to follow, on developing peptide drugs. It lists questions each product must answer: how the body absorbs and clears it, use in people with liver or kidney problems, drug interactions, effects on heart rhythm, and immune reactions.
- 11FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration · 2026-05-31 · FDA document
The page separates approved products from unapproved versions. It notes that side-effect reports sent in voluntarily are incomplete and can't by themselves show that a drug caused a problem.
- 12FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to StabilizeU.S. Food and Drug Administration · 2026-04-01 · FDA document
This FDA policy page says semaglutide and tirzepatide were not on the 503B bulks list or the FDA drug-shortage list on April 1, 2026. It explains the separate rules for the two kinds of compounding pharmacy, 503A and 503B.
- 13Wegovy (semaglutide) Prescribing InformationU.S. Food and Drug Administration · 2026-02-01 · FDA-approved drug label
What the label says about approved uses and safety applies to Wegovy itself and the people the label names. It does not carry over to other semaglutide products or pharmacy-made versions.
- 14Zepbound (tirzepatide) Prescribing InformationU.S. Food and Drug Administration · 2026-02-01 · FDA-approved drug label
What the label says about approved uses and safety applies to Zepbound itself and the people the label names. It does not carry over to other tirzepatide products or pharmacy-made versions.
- 15Once-Weekly Semaglutide in Adults with Overweight or ObesityThe New England Journal of Medicine (PubMed record) · 2021-03-18 · Trial in people
STEP 1 tested one semaglutide plan, along with diet and exercise advice, in adults without diabetes. Its averages can't predict one person's result, and they say nothing about pharmacy-made versions.
- 16Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesThe New England Journal of Medicine (PubMed record) · 2023-12-14 · Trial in people
SELECT included adults who already had heart and blood vessel disease and overweight or obesity, but not diabetes. Its result applies to those people and that product.
- 17Tirzepatide Once Weekly for the Treatment of ObesityThe New England Journal of Medicine (PubMed record) · 2022-07-21 · Trial in people
SURMOUNT-1 tested one tirzepatide product in adults without diabetes. Its group averages promise no result for any one person, and they say nothing about pharmacy-made versions.
- 18Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewHSS Journal (PubMed record) · 2025-07-31 · Review of many studies
The review is useful as a map of the evidence. It found the research was almost all animal and lab studies, and it did not show that BPC-157 works or is safe in people.
- 19PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal InflammationGastroenterology (PubMed record) · 2008-01-01 · Animal or lab study
This study used human cell lines and mouse colitis models. No patients received KPV, and no clinical outcomes were tested.
- 20The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin ResistanceCell Metabolism (PubMed record) · 2015-03-03 · Animal or lab study
The intervention results came from cells and mice. Detecting endogenous MOTS-c in human plasma measures the body's own peptide and tests no treatment.
- 21MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle HomeostasisNature Communications (PubMed record) · 2021-01-20 · Study in people
The part in people measured the body's own MOTS-c around exercise in ten young men. The results on giving MOTS-c, for fitness and aging, came from cells and mice.